Random and site-specific radiolabeling of [89Zr]Zr-DFO-anti-PD-L1-mAb iPET tracer.

Uloženo v:
Podrobná bibliografie
Název: Random and site-specific radiolabeling of [89Zr]Zr-DFO-anti-PD-L1-mAb iPET tracer.
Autoři: Lin, Yi-Ching, Yang, Chao-Wei, Tsai, Shih-Chuan, Farn, Shiou-Shiow, Ou Yang, Fang-Yu, Lo, Wei-Lin, Chen, Liang-Cheng, Chen, Kuo-Ting, Weng, Mao-Chi, Kung, Jui-Yin, Qiu, Xin-Yu, Lu, Ching-Chun, Huang, Feng-Yun J.
Zdroj: Journal of Radioanalytical & Nuclear Chemistry; Nov2024, Vol. 333 Issue 11, p5997-6005, 9p
Témata: RADIOLABELING, CELL death, TOMOGRAPHY, IMMUNOTHERAPY, AUTOMOBILES
Abstrakt: Zirconium-89 radiolabeled immuno-positron emission tomography (89Zr-iPET) has become a critical tool for patient stratification before and after immunotherapies for therapeutic evaluation. In this study, random and site-specific radiolabeling of 89Zr-iPET tracers were investigated. Traditional lysine-based conjugation and enzyme-based GlyCLICK® kit method were used to prepare DFO-anti-PD-L1-mAb conjugates with a chelator-to-antibody ratio (CAR) of 0–7 and 2.0, respectively. Then, conjugates with different CAR levels were radiolabeled with 89Zr to obtain randomly or site-specifically radiolabeled 89Zr-iPET tracer. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Radioanalytical & Nuclear Chemistry is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Databáze: Complementary Index
Popis
Abstrakt:Zirconium-89 radiolabeled immuno-positron emission tomography (<sup>89</sup>Zr-iPET) has become a critical tool for patient stratification before and after immunotherapies for therapeutic evaluation. In this study, random and site-specific radiolabeling of <sup>89</sup>Zr-iPET tracers were investigated. Traditional lysine-based conjugation and enzyme-based GlyCLICK<sup>®</sup> kit method were used to prepare DFO-anti-PD-L1-mAb conjugates with a chelator-to-antibody ratio (CAR) of 0–7 and 2.0, respectively. Then, conjugates with different CAR levels were radiolabeled with <sup>89</sup>Zr to obtain randomly or site-specifically radiolabeled <sup>89</sup>Zr-iPET tracer. [ABSTRACT FROM AUTHOR]
ISSN:02365731
DOI:10.1007/s10967-024-09401-0